Hoosier Oncology is pleased to announce that study LUN05-99 – “Paclitaxel plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC):
A Safety, Feasibility and Efficacy Study” has been accepted by the Journal of Thoracic Oncology. Congratulations to Dr. Jalal and the entire team.

Citation:
Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramaswamy; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser.  Link to Journal.  Journal of Thoracic Oncology. 5(12):2008-2011, December 2010. doi: 10.1097/JTO.0b013e3181f77b6e

Hoosier Cancer Research Network  (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,400 patients have participated in Hoosier Cancer Research Network clinical trials.